Physician profile
Dara F Shalom
NPI 1245498518
$93,613.16
in general payments reported to CMS, 2019-2025
5 companies · $39K in 2025
The $39K reported for 2025 was more than what 98% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.97 · 2020: $17.74 · 2021: $2,322 · 2022: $22K · 2023: $25K · 2024: $5,957 · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Travel and Lodging: $10K · Consulting Fee: $7,000 · Food and Beverage: $4,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,204.00 |
| Travel and Lodging | $10,114.31 |
| Consulting Fee | $7,000.00 |
| Food and Beverage | $4,325.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $80,297.47 | 2019-2025 | Advantage System, Solyx Sis System, Solyx Blue |
| Femselect INC. | $7,499.24 | 2025 | Enplace |
| Axonics, INC. | $5,408.06 | 2023-2024 | Axonics, Bulkamid |
| Coloplast Corp | $384.30 | 2024-2025 | |
| Medtronic USA, INC. | $24.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dara Shalom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.